CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
2022 年 11 月 30 日至 12 月 1 日在那不勒斯举行的 2022 年免疫治疗桥大会上的“大辩论”
英文原题：The "Great Debate" at Immunotherapy Bridge 2022, Naples, November 30th-December 1st, 2022.
查看英文原题
The "Great Debate" at Immunotherapy Bridge 2022, Naples, November 30th-December 1st, 2022.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
2022年免疫治疗桥大会（2022年11月30日至12月1日，意大利那不勒斯）设有一场大型辩论环节，探讨了免疫治疗领域的三个当代议题。辩论包括顶尖专家的对立观点，并审议了过继性细胞治疗（ACT）在实体瘤治疗中是否有作用、外周/血液生物标志物与肿瘤微环境生物标志物在癌症免疫治疗中的应用，以及CAR-T 细胞与NK 细胞治疗的作用。按照免疫治疗桥大型辩论的传统，演讲者由会议主席邀请，表达指定辩论一方观点，所发表的意见可能不完全反映其个人观点。每场辩论前后，观众均对议题的任一方进行投票。
展开英文摘要原文
The 2022 Immunotherapy Bridge congress (November 30-December 1, Naples, Italy) featured a Great Debate session which addressed three contemporary topics in the field of immunotherapy. The debates included counterpoint views from leading experts and considered whether adoptive cell therapy (ACT) has a role in the treatment of solid tumors, the use of peripheral/blood biomarkers versus tumor microenvironment biomarkers for cancer immunotherapy and the role of chimeric antigen receptor T cell versus natural killer cell therapy.
As is the tradition in the Immunotherapy Bridge Great Debates, speakers are invited by the meeting Chairs to express one side of the assigned debate and the opinions given may not fully reflect their own personal views. Audiences voted in favour of either side of the topic both before and after each debate.
论文信息
- 作者
- Ascierto PA、Brentjens R、Khleif SN、Odunsi K、Rezvani K、Ruella M、Sullivan RJ、Fox BA
- 单位
- Department of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy. paolo.ascierto@gmail.com.Italy
- 期刊
- Journal of translational medicine2023 Apr 22
- 原文标识
- PubMed 37087493 · DOI 10.1186/s12967-023-04117-3
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →